ClinicalTrials.gg

Program

WRN Inhibitor MOMA-341

Its studies are mostly in Neoplasm Metastasis, led by MOMA Therapeutics.

Furthest: phase 1, since May 2, 20251 company-led study, 1 open or runningNext primary completion: Nov 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
MOMA Therapeutics11 open or runningphase 1since May 2, 2025May 2, 2025Nov 2027phase 1 · NCT06974110

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 2, 2025First study: phase 1 study in Neoplasm MetastasisFirst studyNCT06974110 · 132 planned · United States, Australia

Ahead

  1. Nov 2027Primary completion: phase 1 study in Neoplasm MetastasisNCT06974110

TargetBeta

WRN →read by rule
“An orally bioavailable allosteric inhibitor of the Werner syndrome ATP-dependent helicase (WRN), ”NCIt, by rule

Other programs on WRN

ProgramCompanyFurthest phaseStudies
WRN Inhibitor RO7589831ruleBayerphase 22
WRN Inhibitor GSK4418959ruleGlaxoSmithKlinephase 21
WRN Inhibitor NDI-219216rulenimbus-wadjet-incphase 21
WRN Inhibitor EIK1005ruleeikon-therapeuticsphase 21
WRN Inhibitor AMG 436ruleAmgenphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06974110Neoplasm Metastasis · United States, Australia1RecruitingNov 2027132

How it is read

Names in the registry

  • “MOMA-341”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.